Publications (438) RAUL JESUS ANDRADE BELLIDO publications

filter_list

2025

  1. Drug-induced Liver Injury in Latin America: 10-year Experience of the Latin American DILI (LATINDILI) Network

    Clinical Gastroenterology and Hepatology, Vol. 23, Núm. 1, pp. 89-102

  2. Epigenetic modifications in drug-induced liver injury: A systematic review

    British Journal of Clinical Pharmacology

  3. Genetic Variants of GBP4: Reduced Risks for Drug-Induced Acute Liver Failure in Non-Finnish European Population

    Liver International, Vol. 45, Núm. 2

  4. IQ DILI Consensus Opinion: Best Practices for Rechallenge Following Suspected Drug-Induced Liver Injury in Clinical Trials

    Drug Safety

  5. Management of drug-induced liver injury associated with anti-cancer therapy

    Frontiers in Physiology

  6. Recurrence of autoimmune hepatitis cholestatic variant syndromes after liver transplantation affects graft and patient survival

    JHEP Reports, Vol. 7, Núm. 5

  7. Reply to: Correspondence on ‘Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network’

    Journal of Hepatology

2024

  1. A global action agenda for turning the tide on fatty liver disease

    Hepatology, Vol. 79, Núm. 2, pp. 502-523

  2. Anticancer drugs are the first cause of drug-induced liver injury in a reference hospital

    Liver International, Vol. 44, Núm. 2, pp. 286-292

  3. Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries

    Archives of Toxicology, Vol. 98, Núm. 1, pp. 303-325

  4. Co-20. Evaluación de la influencia de enfermedades subyacentes en el daño hepático inducido por fármacos

    Revista andaluza de patología digestiva, Vol. 47, Núm. 5, pp. 241-242

  5. Control compounds for preclinical drug-induced liver injury assessment: Consensus-driven systematic review by the ProEuroDILI network

    Journal of Hepatology, Vol. 81, Núm. 4, pp. 630-640

  6. Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative (Drug Safety, (2024), 47, 4, (301-319), 10.1007/s40264-023-01390-5)

    Drug Safety

  7. Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative

    Drug Safety, Vol. 47, Núm. 4, pp. 301-319

  8. Drug-induced autoimmune-like hepatitis

    Clinical Liver Disease, Vol. 23, Núm. 1

  9. Drug-induced liver injury

    Sinusoidal Cells in Liver Diseases: Role in their Pathophysiology, Diagnosis, and Treatment (Elsevier Science Ltd.), pp. 193-212

  10. Emerging role of immunotherapy for cancer as a major cause of drug-induced liver injury

    Annals of Hepatology

  11. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression

    United European Gastroenterology Journal, Vol. 12, Núm. 8, pp. 1056-1068

  12. Hepatitis C virus point-of-care microelimination approach in a vulnerable population in the South of Spain

    Gastroenterology Report, Vol. 12

  13. Hepatopatías por tóxicos y medicamentos.

    Medicina interna (Elsevier España), pp. 318-327